TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22835804

Group type: EXPERIMENTAL
Intervention: CHESS+CM (Comprehensive Health Enhancement Support System + monthly nurse case management via phone)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: CHESS+CM
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (treatment as usual plus asthma information)
Number of subjects: 301
Study: 20427350

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT), cisplatin 40 mg/m² weekly for seven doses plus RT
Number of subjects: 153

Group type: COMPARATOR
Intervention: Radical radiotherapy (RT), 70 Gy/35 fractions over 7 weeks
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Radical radiotherapy (RT)
Number of subjects: 153
Study: 17905018

Group type: EXPERIMENTAL
Intervention: L‐hyoscyamine 0.5 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 16415698

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 31
Study: 12814710

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 5963
Study: 10817552

Group type: EXPERIMENTAL
Intervention: IL-1Ra 30 mg/day
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: IL-1Ra 75 mg/day
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: All IL-1Ra treatment groups combined
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study: 8784014

Group type: EXPERIMENTAL
Intervention: Irradiation after operation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Non-irradiation after operation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Irradiation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Non-irradiation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 132
Study: 1617046

Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 3

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 3
Study: 6228370

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg orally 2 h before exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.216 mg by inhalation 30 min before exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 10
Study: 31435653

Group type: EXPERIMENTAL
Intervention: Ultrasonic Bone Scalpel (UBS)
Number of subjects: 190

Group type: COMPARATOR
Intervention: High-speed rotatory drill
Number of subjects: 190
Study: 31781698

Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional Loading (CL)
Number of subjects: 42
Study: 28743370

Group type: EXPERIMENTAL
Intervention: Vibration group (50Hz, 0.2N or 20g applied on the buccal surface of maxillary canine)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no vibration)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vibration group
Number of subjects: 13
Study: 26171639

Group type: EXPERIMENTAL
Intervention: Manual expression
Number of subjects: 21

Group type: COMPARATOR
Intervention: Electric pump
Number of subjects: 21
Study: 23635884

Group type: EXPERIMENTAL
Intervention: 10% casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) paste
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gel (CHX)
Number of subjects: 622

Group type: COMPARATOR
Intervention: No product (study control [SC])
Number of subjects: 622
Study: 21998174

Group type: EXPERIMENTAL
Intervention: Short-term recall of condom use (last sex act)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Longer-term recall of condom use (over the past month and year)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Condom use with clients
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Condom use with non-paying partners
Number of subjects: 1000
Study: 18330809

Group type: EXPERIMENTAL
Intervention: Orthosis (Thämert Osteomed) with paravertebral/lumbosacral air chamber pads
Number of subjects: 40

Group type: COMPARATOR
Intervention: The same orthosis without air chamber pads
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo body stocking
Number of subjects: 40
Study: 16989497

Group type: EXPERIMENTAL
Intervention: Barnidipine (10-15 mg)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Felodipine (5-10 mg)
Number of subjects: 131
Study: 15284828

Group type: EXPERIMENTAL
Intervention: 200 mg/d, 3 cycles
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 200 mg/d, 6 cycles
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 400 mg/d, 3 cycles
Number of subjects: 186
Study: 10758445

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (4 microg kg‐1) combined with epidural morphine (40 microg kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (4 microg kg‐1) combined with epidural morphine (40 microg kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (only epidural morphine)
Number of subjects: 0
Study: 9172193

Group type: EXPERIMENTAL
Intervention: High contextual interference (random practice)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low contextual interference (blocked practice)
Number of subjects: 48
Study: 1304175

Group type: EXPERIMENTAL
Intervention: .717% fluoride solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: .04% stannous fluoride gel (Gel‐Kam)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 30
Study: 2413097

Group type: EXPERIMENTAL
Intervention: 320 mg of slow release oxprenolol
Number of subjects: 736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 736
Study: 30786849

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 855
Study: 29771607

Group type: EXPERIMENTAL
Intervention: Passive leg movement (PLM) at various joint angle ROMs (0°‐50°, 50°‐100°, 0°‐100°) and angular velocities (fast: 200°/s, slow: 100°/s)
Number of subjects: 12
Study: 27598024

Group type: EXPERIMENTAL
Intervention: FGLS group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 24629559

Group type: EXPERIMENTAL
Intervention: Small store interventions
Number of subjects: 0
Study: 23079770

Group type: EXPERIMENTAL
Intervention: Creatine (10 g daily)
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study: 20732581

Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 14

Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 14
Study: 17593237

Group type: EXPERIMENTAL
Intervention: BIAsp30 (once daily)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: BIAsp30 (twice daily)
Number of subjects: 192

Group type: COMPARATOR
Intervention: OAD-only
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: BIAsp30 (o.d. and b.i.d. pooled)
Number of subjects: 192
Study: 16360963

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 80
Study: 12215234

Group type: EXPERIMENTAL
Intervention: bromocriptine (2.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: haloperidol (2.0 mg)
Number of subjects: 20
Study: 9857924

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.1 IU x kg(‐1) week(‐1) for 1 week, then 0.25 IU x kg(‐1) week(‐1) for 3 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 22
Study: 7611760

Group type: EXPERIMENTAL
Intervention: Tropisetron 2.5 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Tropisetron 5.0 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Tropisetron 10 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Tropisetron (optimal dose)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Laboratory findings
Number of subjects: 97
Study: 2229525

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 20
Study: 356254

Group type: EXPERIMENTAL
Intervention: Hexoprenaline (0.20 mg/puff)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Terbutaline (0.25 mg/puff)
Number of subjects: 15
Study: 30902431

Group type: EXPERIMENTAL
Intervention: Image-guidance system (VERION) and intraoperative aberrometry (ORA System with VerifEye+) with femtosecond laser-assisted cataract surgery
Number of subjects: 78

Group type: COMPARATOR
Intervention: Surgeon's standard of care
Number of subjects: 78
Study: 28100669

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine-calcitonin-fentanyl (BCF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine-fentanyl (BF)
Number of subjects: 60
Study: 25429095

Group type: EXPERIMENTAL
Intervention: HeO2 (21% O2:balance He)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: HeO2
Number of subjects: 21
Study: 24951357

Group type: EXPERIMENTAL
Intervention: Oxytocin (80 units in 500ml of 0.9% normal saline at 2ml/min)
Number of subjects: 86

Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 86
Study: 22300008

Group type: EXPERIMENTAL
Intervention: Prehospital use of tissue plasminogen activator in an ambulance with a stroke emergency mobile unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular care (without stroke emergency mobile unit)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prehospital use of tissue plasminogen activator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety evaluation
Number of subjects: 0
Study: 19008237

Group type: EXPERIMENTAL
Intervention: High risk (HR) group for OSA
Number of subjects: 178

Group type: COMPARATOR
Intervention: Low risk (LR) group for OSA
Number of subjects: 178
Study: 17502411

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 0
Study: 16364832

Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus LBK‐16H fermented milk (150 mL twice daily for 10 weeks)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus LBK‐16H fermented milk
Number of subjects: 94
Study: 11942450

Group type: EXPERIMENTAL
Intervention: BabyCheck
Number of subjects: 497
Study: 9794010

Group type: EXPERIMENTAL
Intervention: Unipolar and bipolar patients with recurrent episodes
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Unipolar and bipolar patients
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Patients with recurrent episodes
Number of subjects: 204

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 204
Study: 7649139

Group type: EXPERIMENTAL
Intervention: 20 min voluntary exercise at 30% of maximal voluntary contraction
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3 min of 10 Hz stimulation after exercise
Number of subjects: 10
Study: 2664340

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Finnish analogue of prazosin
Number of subjects: 0
Study: 1104344

Group type: EXPERIMENTAL
Intervention: KAVOSAN
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 43
Study: 30999969

Group type: EXPERIMENTAL
Intervention: HandScan-guided treatment aimed at 'HandScan remission' (HandScan arm)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Clinically guided treatment aimed at ACR/EULAR 2011 Boolean remission (DAS arm)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: HandScan-guided treatment
Number of subjects: 122

Group type: COMPARATOR
Intervention: Clinically guided treatment
Number of subjects: 122
Study: 28393444

Group type: EXPERIMENTAL
Intervention: Technique III: intermittent SVC clamping
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Technique II: superior vena cava (SVC) cannulation
Number of subjects: 75

Group type: COMPARATOR
Intervention: All techniques of BDG
Number of subjects: 75
Study: 26099869

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 18

Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 18
Study: 24206099

Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.0-1.4 mg/kg/day)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 21681159

Group type: EXPERIMENTAL
Intervention: Warm Water (WW) at 38 °C for 30 minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cold Water (CW) at 20 °C for 30 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CO) with no intervention
Number of subjects: 60
Study: 19436141

Group type: EXPERIMENTAL
Intervention: Diet V (increased vegetable consumption)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Diet C (increased cereal consumption)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study: 16923002

Group type: EXPERIMENTAL
Intervention: Bipolar, lumenless, catheter-delivered pacemaker lead (Model 3830)
Number of subjects: 338
Study: 15168891

Group type: EXPERIMENTAL
Intervention: Multivitamins plus creatine (amount equal to twice daily creatinine excretion) for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multivitamins (control group) for four weeks
Number of subjects: 0
Study: 14674495

Group type: EXPERIMENTAL
Intervention: EC 40 (EC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cervitec (CE)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prime and Bond NT (PB)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Seal & Protect (SP)
Number of subjects: 22
Study: 10468866

Group type: EXPERIMENTAL
Intervention: rhIL‐3 10 microgram/kg/d
Number of subjects: 198

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: rhIL‐3
Number of subjects: 198
Study: 8645788

Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily for 14 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily for 7 or 14 days)
Number of subjects: 9
Study: 2083857

Group type: EXPERIMENTAL
Intervention: Solution VI (glucose 80, sodium 30, potassium 20 mmol/l; 177 mOsm/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solution II (WHO oral rehydration solution; glucose 111, sodium 90, bicarbonate 30, potassium 20; 308 mOsm/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solution IV (glucose 111, sodium 60, potassium 20 mmol/l; 260 mOsm/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solution III (hypertonic commercial oral rehydration solution; glucose 188, sodium 50, bicarbonate 20, potassium 20 mmol/l; 335 mOsm/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solution V (glucose 80, sodium 60, potassium 20 mmol/l; 219 mOsm/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Solution I (standard cleansing solution; sodium 125, potassium 10, bicarbonate 20, sulphate 40, mannitol 80 mmol/l; 275 mOsm/kg)
Number of subjects: 0
Study: 6985775

Group type: EXPERIMENTAL
Intervention: Gastrointestinal staples
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 100
Study: 27825893

Group type: EXPERIMENTAL
Intervention: Serelaxin (30 µg ⋅ kg‐1 ⋅ d‐1 intravenous infusion for 48 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 0
Study: 26477635

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 802

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 802
Study: 23635860

Group type: EXPERIMENTAL
Intervention: Diquafosol sodium (DQS) eye drops
Number of subjects: 56

Group type: COMPARATOR
Intervention: Artificial tears (AT)
Number of subjects: 56
Study: 22136774

Group type: EXPERIMENTAL
Intervention: Transoral gastroplasty (TOGA)
Number of subjects: 67
Study: 18637106

Group type: EXPERIMENTAL
Intervention: Distance single-vision spectacles with 'head neutral-gaze down'
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Distance single-vision spectacles with 'head flexed-gaze down'
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Distance single-vision spectacles with 'head neutral-gaze forward'
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Multifocal spectacles with 'head neutral-gaze down'
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Multifocal spectacles with 'head flexed-gaze down'
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Multifocal spectacles with 'head neutral-gaze forward'
Number of subjects: 18
Study: 16706261

Group type: EXPERIMENTAL
Intervention: Pen-and-paper coronary risk estimator
Number of subjects: 535
Study: 15263050

Group type: EXPERIMENTAL
Intervention: Antidepressants and psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11673101

Group type: EXPERIMENTAL
Intervention: CDSS in psychiatry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDSS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 9144118

Group type: EXPERIMENTAL
Intervention: Standard glucose-based ORS in alternation with soy-based, lactose-free infant formula (Group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rice syrup solid containing ORS in alternation with rice-based, lactose-free infant formula (Group 2)
Number of subjects: 0
Study: 8081520

Group type: EXPERIMENTAL
Intervention: Acute drug therapy using sumatriptan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute drug therapy using MK‐462
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute drug therapy using 311C90
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute drug therapy using dihydroergotamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute drug therapy using nonsteroidal anti‐inflammatory drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute drug therapy using butorphanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute drug therapy using metoclopramide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute drug therapy using domperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic drug therapy using valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic drug therapy using fluoxetine
Number of subjects: 0
Study: 31948301

Group type: EXPERIMENTAL
Intervention: Spinal chiropractic manipulative therapy (SCMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard AMS pain control
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SCMT
Number of subjects: 100
Study: 30304077

Group type: COMPARATOR
Intervention: Control group (only sutures applied)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Periodontal dressing material group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hemostatic gelatin sponge group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gelatin sponge combined with cyanoacrylate group
Number of subjects: 50
Study: 27053407

Group type: EXPERIMENTAL
Intervention: ARB + CCB
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: ACEI + CCB
Number of subjects: 168

Group type: COMPARATOR
Intervention: beta-blocker + diuretic
Number of subjects: 168

Group type: COMPARATOR
Intervention: ACEI + diuretic
Number of subjects: 168

Group type: COMPARATOR
Intervention: angiotensin II receptor blocker (ARB) + diuretic
Number of subjects: 168
Study: 26859013

Group type: EXPERIMENTAL
Intervention: Intensive FP counselling
Number of subjects: 127

Group type: COMPARATOR
Intervention: Routine FP counselling
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Post-placental IUCD
Number of subjects: 127
Study: 22857944

Group type: EXPERIMENTAL
Intervention: Dual task condition (cognitive task during gait)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no cognitive task during gait)
Number of subjects: 59
Study: 20676545

Group type: EXPERIMENTAL
Intervention: Transobturator sling surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Retropubic sling surgery
Number of subjects: 30
Study: 18706007

Group type: EXPERIMENTAL
Intervention: Combined i.v./i.a. approach to recanalization (lower dose of i.v. rt-PA approximately 0.6 mg/kg, 60 mg maximum over 40 min, followed by angiography and possible i.a. therapy)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard i.v. rt-PA alone (full dose 0.9 mg/kg, 90 mg maximum over 1 hour)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Combined i.v./i.a. approach to recanalization
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard i.v. rt-PA alone
Number of subjects: 900
Study: 17261975

Group type: EXPERIMENTAL
Intervention: Reinstitution or continuation of GH therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing GH therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of childhood GH replacement therapy without restart in adults
Number of subjects: 0
Study: 12663289

Group type: EXPERIMENTAL
Intervention: HIGHNAT-E formula (20 IU RRR-alpha-tocopheryl acetate/L, 14.5 mg/L)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: LOWNAT-E formula (10 IU RRR-alpha-tocopheryl acetate/L, 7.3 mg/L)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: SYN-E formula (13.5 IU synthetic all-rac-alpha-tocopheryl acetate/L, 13.5 mg/L)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Human milk-fed group (n = 29)
Number of subjects: 77
Study: 10809343

Group type: EXPERIMENTAL
Intervention: Oral suspension (200 mg phenytoin)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Rectal suppository (200 mg phenytoin)
Number of subjects: 6
Study: 8841210

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms per vagina every 4 hours as needed
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard approach (physician‐chosen combinations of intracervical or vaginal dinoprostone every 6 hours, artificial rupture of membranes, and oxytocin infusion)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 222
Study: 1338088

Group type: EXPERIMENTAL
Intervention: 100 mg SPFX
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 200 mg SPFX
Number of subjects: 91
Study: 6229975

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 28627220

Group type: EXPERIMENTAL
Intervention: Exploratory bifactor model for the PSS
Number of subjects: 11939

Group type: EXPERIMENTAL
Intervention: Confirmatory bifactor model for the PSS
Number of subjects: 11939

Group type: EXPERIMENTAL
Intervention: PSS factors analysis
Number of subjects: 11939